Hospital General Universitario Gregorio Maranon

Research at Hospital General Universitario Gregorio Maranon focuses on blood‑related cancers, aiming to improve survival and reduce treatment‑related toxicity.

• Acute myeloid leukemia
• Chronic myeloid leukemia
• Acute lymphoblastic leukemia
• Multiple myeloma
• Mantle cell lymphoma
• Diffuse large B‑cell lymphoma
• Myelodysplastic syndromes
• Chronic lymphocytic leukemia

Additional info: trials test novel targeted agents, cellular therapies and maintenance strategies to achieve deeper remissions.

Investigations target a broad range of solid tumors, evaluating new targeted drugs and combination regimens to extend progression‑free survival.

• Breast cancer
• Non‑small cell lung cancer
• Colorectal cancer
• Melanoma
• Gastric cancer
• Pancreatic ductal adenocarcinoma
• Renal cell carcinoma
• Hepatocellular carcinoma
• Sarcoma

Additional info: many studies incorporate biomarker‑driven enrollment such as KRAS, EGFR, HER2, and PD‑L1 status.

Trials address immune‑mediated conditions, testing innovative biologics and small molecules to control disease activity.

• Systemic lupus erythematosus
• Immune thrombocytopenia
• Atopic dermatitis
• Psoriasis
• Multiple sclerosis
• Rheumatoid arthritis
• Inflammatory bowel disease
• Chronic graft‑versus‑host disease

Additional info: objectives include improving quality of life and reducing flare frequency.

Research explores therapies for heart disease and metabolic disorders, seeking to lower event rates and improve organ function.

• Acute myocardial infarction
• Heart failure with reduced ejection fraction
• Atherosclerotic cardiovascular disease
• Type 2 diabetes
• Metabolic dysfunction‑associated steatohepatitis
• Hypertension

Additional info: studies often evaluate anti‑inflammatory or metabolic pathways such as IL‑6 inhibition.

Clinical work includes chronic liver conditions and digestive‑tract cancers, aiming to halt disease progression and alleviate symptoms.

• Non‑alcoholic steatohepatitis
• Primary biliary cholangitis
• Cholestatic pruritus
• Hepatitis B
• Colorectal cancer
• Gastric adenocarcinoma
• Biliary tract cancer

Additional info: endpoints frequently involve liver fibrosis regression and patient‑reported itch scores.

Studies address severe infections and post‑transplant complications, testing antivirals, antibiotics, and immune‑modulating protocols.

• COVID‑19
• Acute graft‑versus‑host disease
• Cytomegalovirus infection
• Clostridioides difficile infection
• Invasive fungal infections
• Transplant rejection

Additional info: safety and infection‑control outcomes are primary measures.